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Abstract
Aside from a decrease in the high-density lipoprotein (HDL) cholesterol levels, qualitative abnormalities of HDL can
contribute to an increase in cardiovascular (CV) risk in end-stage renal disease (ESRD) patients undergoing chronic
hemodialysis (HD). Dysfunctional HDL leads to an alteration of reverse cholesterol transport and the antioxidant and anti-
inflammatory properties of HDL. In this study, a quantitative proteomics approach, based on iTRAQ labeling and nanoflow
liquid chromatography mass spectrometry analysis, was used to generate detailed data on HDL-associated proteins. The
HDL composition was compared between seven chronic HD patients and a pool of seven healthy controls. To confirm the
proteomics results, specific biochemical assays were then performed in triplicate in the 14 samples as well as 46 sex-
matched independent chronic HD patients and healthy volunteers. Of the 122 proteins identified in the HDL fraction, 40
were differentially expressed between the healthy volunteers and the HD patients. These proteins are involved in many HDL
functions, including lipid metabolism, the acute inflammatory response, complement activation, the regulation of
lipoprotein oxidation, and metal cation homeostasis. Among the identified proteins, apolipoprotein C-II and apolipoprotein
C-III were significantly increased in the HDL fraction of HD patients whereas serotransferrin was decreased. In this study, we
identified new markers of potential relevance to the pathways linked to HDL dysfunction in HD. Proteomic analysis of the
HDL fraction provides an efficient method to identify new and uncharacterized candidate biomarkers of CV risk in HD
patients.
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Introduction
In the general population, a decrease in high-density lipoprotein
(HDL) cholesterol and/or dysfunctional HDL is recognized as an
important risk factor in cardiovascular (CV) diseases [1,2]. Several
studies have focused on the protective effects of HDL on low-
density lipoprotein (LDL) oxidation in the arterial wall [3]. HDL is
now recognized to protect against plaque formation and
progression, in part, through the transport of cholesterol from
the peripheral tissues to the liver [4]. The other biological activities
of HDL are related to their protein component and are vital in the
atheroprotective effects of HDL. Of particular importance are the
potent antioxidative and anti-inflammatory activities of HDL,
which can directly inhibit LDL oxidation and LDL-induced
monocyte infiltration [1,3]. However, in chronic and acute
inflammation, HDL can also have pro-oxidative and proinflam-
matory properties [1,5–7].
End-stage renal disease (ESRD) patients undergoing chronic
hemodialysis (HD) are prone to lipid disorders, chronic inflamma-
tion and oxidative stress that contribute to the acceleration of
atherosclerosis [8–12]. CV diseases are recognized as the major
cause of mortality and morbidity in HD patients [15–16]. Lipid
disorders in HD patients are mainly related to ESRD-induced
alterationsinlipoproteinmetabolism,especiallytheaccumulationof
very-low-density lipoproteins (VLDL), a shift in the LDL subclass
and alterations in HDL maturation [12,17]. Patients usually display
elevated triglycerides, unchanged or even reduced LDL cholesterol,
and decreased HDL cholesterol [13,14]. In addition, the HD
procedure itself can worsen the lipid profile by further decreasing
the HDL cholesterol and increasing the LDL cholesterol levels after
a session [18]. Aside from a decrease in HDL cholesterol, the CV
risk in HD patients is also enhanced by the qualitative abnormalities
that lead to dysfunctional HDL [19–22].
Because the HDL proteome is involved in HDL functionality,
we applied a quantitative proteomics approach to investigate the
proteins associated with HDL in HD patients and healthy subjects.
We used 8-plex iTRAQ reagents and 2D nanoflow liquid
chromatography-mass spectrometry analysis (2D nano-LC/MS/
MS) to identify the qualitative and quantitative differences in the
proteins purified from the HDL fractions between the HD patients
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potential relevance in lipid metabolism and the oxidative and
inflammatory pathways that could be linked to the HDL
dysfunction in HD patients. The identification of new relevant
markers could further be used to evaluate the CV risk related to
the abnormal HDL proteome.
Materials and Methods
Ethics statement
The patients were recruited from the Department of Nephrol-
ogy using protocols approved by the institutional review board of
the University Hospital of Montpellier. Informed consent was
obtained from all patients.
Patient selection
Seven chronic HD patients on renal replacement therapy and
seven healthy volunteers were included in the discovery study
population. The validation study population consisted of 23
additional sex-matched HD patients and 23 healthy volunteers.
The validation study population was sex-matched but not age-
matched. The absence of age-matching in the validation study
population should be considered a limitation. All HD patients
received online hemodiafiltration treatments three times per week,
with ultra-pure bicarbonate-based dialysate using a high flux
polysulfone membrane (HF-80, Fresenius). Three patients received
fibrates, and 13 patients received statins (Table S1). Blood samples
were collected on the arterial line before the mid-week dialysis
session. All the healthy volunteers were blood donors for the
French Blood Agency. Individuals exhibiting acute or chronic
infection, hypertension, or diabetes and those requiring medica-
tions were excluded. Blood sampling was performed during the
blood donation. The plasma was obtained using EDTA-coated
tubes, by centrifugation at 3,000 rpm for 15 min, and was stored
at 280uC before analysis. All samples were collected during the
same month and were subjected to the same number of freeze/
thaw cycles (n=2, before HDL isolation and before proteomic or
biochemical analysis).
Human plasma HDL isolation
The HDL fraction (d=1.063–1.21 g/ml) from each sample was
isolated from the plasma by sequential density ultracentrifugation
in three steps using potassium bromide (KBr), as previously
described by Morena et al. [22]. Briefly, the VLDL and LDL were
sequentially removed by ultracentrifugation at 70,000 rpm for 4 h
at 4uC after the adjustment of the plasma density to 1.019 and
1.063 g/ml with KBr, respectively. The HDL fraction was
obtained by adjusting the infranatant density to 1.21 g/ml with
KBr prior to ultracentrifugation. The HDL fraction was dialyzed
against PBS for 24 h at 4uC. Aliquots of the HDL samples were
stored at 280uC. The protein concentration was measured in
triplicate using the Micro BCA Kit (Pierce). The purity of the
HDL fraction was assessed through the measurement of the
apolipoprotein (apo) A-I and apoB levels by immunonephelo-
metric assay (Immage 800, Beckman). All samples exhibited an
apoB level under the limit of detection (i.e. ,0.35 g/L) and an
apoA-I level from 1.50 to 5.70 g/L (Table S1).
Biochemical analyses
The quantification of the total cholesterol, HDL cholesterol,
and triglycerides in the plasma and in the HDL fraction was
determined using routine assays on the chemistry analyzer
Architect C8000 (Abbott). In the HDL fraction, the phospholipid
concentration was determined on the same analyzer using reagent
from the Diasys Diagnostic System. The quantification of
serotransferrin (reagent from Beckman), apoC-II and apoC-III
(reagent from Randox), in the HDL fraction, was performed by
immunoturbidimetric assay on an AU640 analyzer (Beckman).
Haptoglobin, in the HDL fraction, was measured using the
AssayMax Haptoglobin ELISA kit (AssayPro). All assays were
performed in triplicate. The mean individual data are shown in
Table S1.
iTRAQ reagent labeling and peptide processing
The experimental design used for this study is illustrated in
Figure S1. A pool of seven healthy volunteers was used as a
reference ‘‘control sample’’, against which all of the HD patients
were compared. By pooling the healthy samples, the potential loss
of statistical power arising from a reduced sample size is offset by
the reduction in the standard error of the means. iTRAQ labeling
was performed according to the manufacturer’s protocol (AB
Sciex). Briefly, 50 mg of proteins from the HDL control pool and
from the seven HD patients was precipitated using four volumes of
acetone. The pelleted proteins were dissolved into 500 mM
triethylammonium bicarbonate/1% SDS. The proteins were
reduced with 5 mM tris-(2-carboxyethyl) phosphine, alkylated
with 10 mM methyl methane-thiosulfonate, and trypsin digested
overnight. The resulting peptides were labeled for two hours with
one of the eight isobaric amine-reactive tags (Figure S1). The
labeled peptides were combined and cleaned up using a strong
cation exchange cartridge, according to the manufacturer’s
recommended protocol (AB Sciex). The strong cation exchange
eluents were desalted using an Oasis HLB extraction cartridge
(Waters Corporation) and vacuum dried before IEF separation.
The peptides were separated using the Agilent 3100 OFFGEL
Fractionator (Agilent). Briefly, an IPG Drystrip (24 cm, pH 3–10)
was rehydrated for 15 min with 20 ml/well of a solution containing
0.25% IPG buffer, pH 3–10 (GE Healthcare). The desalted
peptides were dissolved in the 0.25% IPG buffer, pH 3–10, and
the peptide solution (150 ml) was pipetted into each well. Twenty-
four well fractionations were focused for 50 kVh, with a maximum
current of 50 mA and power of 200 mW. The fractions were
purified using OMIX C18 100 ml pipette tips (Varian). The
peptides were eluted and lyophilized before being reconstituted for
the 2D nano-LC/MS/MS analysis.
Mass spectrometry analysis of the protein extracts
The peptides were separated using an Ultimate 3000 nano-LC
system coupled to a Probot
TMMicrofraction Collector (Dionex).
The nano-LC separations were performed using an Acclaim
PepMap
TM(C18,3 mm,100 A ˚)7 5mm/15 cmcolumn.Themobile
phases used were 2% acetonitrile (ACN) with 0.05% trifluoroacetic
acid (TFA) (A) and 80% ACN with 0.05% TFA (B). The gradient
elution steps were performed with a flow rate of 0.3 ml/min as
follows: 0–50%B over 60 min,50–80%B over30 min,80–100%B
over 5 min, and then 100% B for an additional 10 min. The
fractions were mixed directly with the matrix-assisted laser
desorption/ionization (MALDI) matrix solution (2 mg/ml a-
cyano-4-hydroxycinnamic acid in 70% ACN with 0.1% TFA) at
a flow rate of 1.2 ml/min. Forty fmol of human [Glu1]
Fibrinopeptide B (m/z 1570.57) was spiked into each spot as an
internal standard. Spotting onto the Opti-TOF
TM LC/MALDI
insert plates (AB Sciex) was performed using the Probot spotting
device over a 110-min period at a speed of 11 s per well.
The plates were analyzed using a MALDI time of flight
(MALDI TOF/TOF) 4800 mass spectrometer (AB Sciex). MS
spectra from m/z 700 to 4000 were acquired in positive reflector
ion mode using 750 laser shots. The ten most abundant peptide
HDL-Associated Proteins in Hemodialysis
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50, were selected for MS/MS analysis using 2500 laser shots from
m/z 300 to 1500.
Data analysis and interpretation
The protein identification and quantification were performed
with the ProteinPilot
TM Software 2.0.1 (AB Sciex). The MS/MS
spectra obtained were searched against the UniProt database
(UniProtKB release 2009_09). The search parameters for tryptic
cleavage and accuracy are built-in functions of the software. The
other data analysis parameters were as follows: 8-plex iTRAQ
peptide labeling, cys-alkylation by MMTS, biological modifica-
tions, a thorough identification search, and a minimum detected
protein threshold of 1.3 (which corresponds to a confidence score
of 95%). The unused protein score, calculated by ProteinPilot, is a
measurement of the confidence in the protein identification after
taking into account all of the peptide data for a given protein and
excluding any evidence that is better explained by a higher ranking
protein. Proteins comprising one or more peptides with a high
confidence score (.95%) and a low false discovery rate (FDR)
(estimated local FDR of 5%) were considered positively identified.
A reversed-decoy database from the same UniProt database was
used to estimate the local FDR using the Proteomics System
Performance Evaluation Pipeline (PSPEP) tool [23]. The use of a
5% local FDR indicates that each protein identified has at least a
95% probability of being correct.
The relative quantification was based on the ratio of the areas
under the reporter peaks, from the control samples (m/z 113 Da)
and the patient samples (m/z 114, 115, 116, 117, 118, 119, and
121 Da). The following criteria were required to select a protein for
further analysis: two or more unique peptides with a high
confidence score (.95%), a p-value for protein quantification
,0.05, greater than a 1.3-fold difference relative to the control
sample, and detection of the protein in more than 50% of the HD
patient samples (at least 4 of the 7 HD patient samples). For more
information about the quantification methodology, see the Text S1.
Statistical analysis
The results are expressed as the mean 6 standard error of the
mean (SEM). The statistical analyses were performed using the
Mann-Whitney U test using GraphPad InStat. A p-value of ,0.05
was chosen for statistical significance. The enrichment analysis of
the gene ontology (GO) was determined using the DAVID
bioinformatics resources [24]. The significance of the gene-term
enrichment was determined using a modified Fischer’s exact test
(EASE score), which ranks the overrepresented GO processes.
Results
Proteomic HDL analysis of the discovery population
The characteristics of the patients, for both study populations,
are summarized in Table 1 and Table S1. In the discovery and in
the validation set, the HD patients exhibited significantly lower
cholesterol levels than the healthy subjects, including lower HDL
cholesterol and lower LDL cholesterol levels. There was no
difference in the plasma triglyceride levels between the HD and
healthy subjects, in either the discovery or the validation set.
Using iTRAQ labeling and 2D nano-LC/MS/MS, a total of
303 non-redundant proteins were identified and quantified for the
comparison between the seven individual HD patients and the
seven healthy volunteers. Among these proteins, 122 were further
selected using stringent criteria, such as containing one or more
peptides with a .95% confidence score and a 5% local FDR. The
complete MS and MS/MS data are shown in Table S2 and Table
S3.
The iTRAQ peptide labeling efficiency was 98.8%. Only 40 of
the 122 proteins showed a differential expression in the HD
patients that also corresponded to our selection criteria (identified
and quantified in at least four of the seven HD patients, a
differential expression of at least 1.3-fold relative to the control
samples, and a p-value,0.05). The complete list of the proteins
defined by these criteria and confidently identified, containing at
least two peptides with a high confidence score, is shown in
Table 2. Among the 40 selected proteins, more than 68% were
found to be differentially expressed in at least six of the HD
patients (10 were upregulated and 17 were downregulated)
compared with the healthy subjects.
The biological processes and the molecular functions of all of
the proteins identified in the HDL fraction were classified using a
GO classification system and are presented in Table S4. The
Table 1. Clinical characteristics of the study population.
Discovery set Validation set
Healthy n=7 HD n=7 p-value
* Healthyn=23 HDn=23 p-value
*
Gender 3M/4F 3M/4F NS 15M/8F 15M/8F NS
Age (years) 59.760.36 69.163.59 NS 56.660.76 69.763.01 ,0.05
Plasma (mmol/L, mean ± SEM)
Total cholesterol 5.460.44 3.760.38 ,0.05 5.060.23 3.760.21 ,0.05
Triglyceride 1.560.25 1.560.37 NS 1.360.11 1.560.19 NS
HDL-Cholesterol 1.760.13 1.160.23 ,0.05 1.460.07 1.060.07 ,0.05
LDL-Cholesterol 3.060.35 1.860.24 ,0.05 2.960.20 1.960.13 ,0.05
HDL (mmol/L, mean 6 SEM)
Total cholesterol 4.860.41 5.461.01 NS 4.760.43 5.260.40 NS
Triglyceride 0.460.05 0.560.09 NS 0.460.05 0.760.13 ,0.05
Phospholipids 3.760.22 4.560.56 NS 3.760.29 4.560.32 ,0.05
Total lipids 8.960.60 10.461.58 NS 8.860.75 10.560.75 NS
*Mann-Whitney test.
doi:10.1371/journal.pone.0034107.t001
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such as lipid and cholesterol transport, lipid metabolism, inflam-
matory response, the complement and coagulation cascade, the
response to metal ions, hemostasis, and endopeptidase inhibitory
activity. We investigated the enrichment of the 40 differentially
expressed proteins using the functional classification tool. Table 3
shows the GO categories associated with the 40 differentially
expressed proteins. Individual mapping of the upregulated and
downregulated proteins shows that the lipid/cholesterol transport
and metabolism proteins were the most significant functional
processes represented by the upregulated proteins, whereas the
acute inflammatory response, complement activation, and endo-
Table 2. iTRAQ ratios for the healthy and HD samples: HD patient samples (HD1-7) vs. pooled healthy subject samples.
Uniprot accession n6 Gene symbol Protein name HD 1 HD 2 HD 3 HD 4 HD 5 HD 6 HD 7
Upregulated
P02652 APOA2 Apolipoprotein A-II 1.86 3.31 2.86 1.34 2.57 2.45 2.30
P02656 APOC3 Apolipoprotein C-III 3.24 3.11 2.65 2.84 3.65 3.70 1.94
P02760 AMBP Protein AMBP 1.41 1.97 1.58 1.85 1.94 1.91 1.42
P05090 APOD Apolipoprotein D 1.51 1.41 1.30 1.56 1.72 1.63 1.49
P02655 APOC2 Apolipoprotein C-II 2.64 2.97 2.87 3.00 4.42 4.43 2.11
P35542 SAA4 Serum amyloid A-4 protein 1.99 2.35 1.54 1.53 1.52 2.76 1.80
P08519 LPA Apolipoprotein(a) 2.81 1.60 1.43 2.83 1.14 2.81 1.79
P02753 RBP4 Retinol-binding protein 4 1.80 2.18 1.25 1.96 1.45 1.60 1.59
P02654 APOC1 Apolipoprotein C-I 1.37 1.79 2.05 1.54 1.96 2.49 1.84
P04180 LCAT Phosphatidylcholine-sterol acyltransferase 2.46 1.72 1.57 1.39 1.54 1.74 1.33
P06727 APOA4 Apolipoprotein A-IV 1.12 2.05 1.39 2.55 1.20 1.71 1.54
P02649 APOE Apolipoprotein E 1.01 1.49 1.09 2.94 1.34 2.62 1.81
P02735 SAA1 Serum amyloid A protein 1.42 1.32 1.32 0.80 8.90 3.43 0.96
O95445 APOM Apolipoprotein M 1.66 1.44 1.28 1.58 1.31 1.40 1.14
P27169 PON1 Serum paraoxonase/arylesterase 1 2.32 1.47 0.97 1.56 1.98 1.10 1.60
P55056 APOC4 Apolipoprotein C-IV 1.35 2.16 1.30 1.99 2.27 2.88 0.83
O14791 APOL1 Apolipoprotein L1 1.78 2.00 1.19 0.91 1.31 1.33 1.02
P04114 APOB Apolipoprotein B-100 1.41 1.39 1.10 1.21 1.98 1.56 1.10
P61769 B2M Beta-2-microglobulin 2.14 3.68 3.73 2.12 3.69 3.74 3.29
Downregulated
P02787 TF Serotransferrin 0.36 0.36 0.43 0.57 0.32 0.43 0.48
P01024 C3 Complement C3 0.65 0.54 0.65 0.71 0.55 0.64 0.58
P02675 FGB Fibrinogen beta chain 0.47 0.50 0.39 0.51 0.33 0.36 0.38
P00738 HP Haptoglobin 0.39 0.27 0.33 0.44 0.37 0.32 0.47
P01876 IGHA1 Ig alpha-1 chain C region 0.34 0.33 0.32 0.62 0.36 0.36 0.41
P01023 A2M Alpha-2-macroglobulin 0.24 0.19 0.25 0.25 0.20 0.24 0.22
P02679 FGG Fibrinogen gamma chain 0.58 0.37 0.33 0.54 0.35 0.39 0.39
P08603 CFH Complement factor H 0.47 0.32 0.48 0.64 0.37 0.42 0.48
P01842 IGLC1 Ig lambda chain C regions 0.45 0.37 0.59 0.60 0.35 0.36 0.53
P01871 IGHM Ig mu chain C region 0.45 0.22 0.30 0.50 0.28 0.26 0.33
P02751 FN1 Fibronectin 0.44 0.34 0.34 0.57 0.32 0.29 0.36
P02671 FGA Fibrinogen alpha chain 0.49 1.02 0.55 0.69 0.40 0.44 0.50
P02790 HPX Hemopexin 0.46 0.46 0.53 0.81 0.47 0.68 0.64
P01042 KNG1 Kininogen-1 0.57 0.71 0.75 0.92 0.43 0.77 0.66
P00734 F2 Prothrombin 0.47 0.46 0.56 0.70 0.52 0.77 0.73
P04196 HRG Histidine-rich glycoprotein 0.38 0.53 0.49 0.88 0.37 0.53 0.58
Q14624 ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4 0.69 0.39 0.55 0.60 0.35 0.58 0.58
P04004 VTN Vitronectin 0.60 0.61 0.54 0.71 0.48 0.66 0.65
P01008 SERPINC1 Antithrombin-III 0.64 0.68 0.85 1.00 0.67 0.73 0.82
P10909 CLU Clusterin 0.67 0.58 0.77 1.09 0.62 0.93 0.86
P01700 LV102 Ig lambda chain V-I region HA 0.42 0.45 0.40 0.49 0.21 0.25 0.38
Ratios of at least 1.3-fold relative to the control samples, and a p-value,0.05 are indicated in bold.
doi:10.1371/journal.pone.0034107.t002
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processes represented by the downregulated proteins.
Confirmation of the differential levels of HDL-associated
proteinsin the discovery study population by
biochemical analysis
A panel of four proteins identified by MS analysis in all seven
HD patients (two upregulated [apoC-II and apoC-III] and two
downregulated [serotransferrin and haptoglobin]) was selected to
confirm the changes in the protein expression that was observed in
the proteomic analysis. These four proteins were quantified in the
same population using biochemical or immunological assays. The
results were in agreement with the MS findings, and we showed a
significant correlation between the iTRAQ and the biochemical
quantification ratio for the four proteins (Table 4). There were no
significant differences between the iTRAQ and the biochemical
quantification ratios, except for apoC-II and serotransferrin
(Table 4). The comparison of the iTRAQ reporter ion signal
intensities revealed a 3.11-fold increase and a 0.41-fold decrease in
apoC-II and serotransferrin, respectively, in the HD patients as
compared with the control pool. These results are consistent with
the 6.53-fold increase and 0.14-fold decrease, respectively,
detected by the biochemical quantification using the same
samples, even if the magnitude of observed change is far greater
than that seen in the iTRAQ assay (p-value,0.05 and p-
value,0.005 for apoC-II and serotransferrin, respectively). When
we compared the expression of each protein, the expression of
apoC-II and apoC-III were significantly higher in the HDL
fraction of the HD patients when compared with the healthy
volunteers whereas serotransferrin and haptoglobin showed
significantly lower expression in the HDL fraction of the HD
patients when compared with the healthy volunteers (Figure 1A).
Differential levels of the HDL-associated proteins in an
independent validation study population
We quantified apoC-II, apoC-III, serotransferrin and hapto-
globin in the HDL fraction of 23 additional healthy control
volunteers and 23 sex-matched HD patients (Table 5 and
Figure 1B). The apoC-II in the HDL fraction was confirmed to
be significantly higher in the HD patients (11.4 mg/mg of protein,
Table 3. The gene ontology category enrichments for the differentially expressed proteins in the HDL fraction.
Gene Ontology Category P-value
* iTRAQ expression Gene symbol
Acute inflammatory response (GO:0002526) 4.00E-11 Down-regulated FN1. TF. KNG1. ITIH4. CFH. CLU. C3. A2M. F2
Endopeptidase inhibitor activity (GO:0004866) 9.00E-07 Down-regulated HRG. KNG1. ITIH4. SERPINC1. C3. A2M
Heparin binding (GO:0008201) 2.10E-06 Down-regulated HRG.FN1. SERPINC1. VTN
Complement and coagulation cascade
(KEGG hsa04610)
3.30E-14 Down-regulated FGG. FGA. KNG1. FGB. SERPINC1. CFH. C3. A2M. F2
Cation homeostasis (GO:0055080) 3.80E-04 Down-regulated TF. KNG1. HP. HPX. F2
Lipid transport (GO:0006869) 5.00E-26 Up-regulated RBP4. APOB. APOA4. LCAT. LPA. APOL1. APOE.
APOC2. APOC3. APOM. APOA2. APOC4. APOC1
Cholesterol transport (GO:0030301) 2.70E-19 Up-regulated APOB. APOA4. LCAT. APOE. APOC2. APOC3. APOM.
APOA2. APOC1
Cholesterol metabolic process (GO:0008203) 2.40E-13 Up-regulated APOB. APOA4. LCAT. APOL1. APOE. APOC3. APOA2.
APOC1
Lipid metabolic process (GO:0019216) 1.20E-12 Up-regulated APOB. APOA4. APOE. APOC2. APOC3. APOM. APOA2.
APOC1
Regulation of lipoprotein oxidation
(GO:0034442)
5.60E-06 Up-regulated PON1. APOA4. APOM
*Enrichment P-values were calculated using a modified Fischer’s exact test (EASE score).
doi:10.1371/journal.pone.0034107.t003
Table 4. Comparison of the iTRAQ ion ratios and the biochemical quantification ratios.
Protein name Ratio HD 1 HD 2 HD 3 HD 4 HD 5 HD 6 HD 7 Mean Correlation
Pearson r p-value
Apolipoprotein C-II iTRAQ 2.64 2.97 2.87 3 4.42 4.43 2.11 3.11 0.89 0.008
Quant 5.12 5.3 3.66 8.89 9.53 11.51 1.71 6.53
Apolipoprotein C-III iTRAQ 3.24 3.11 2.65 2.84 3.65 3.7 1.94 2.96 0.85 0.03
Quant 1.38 3.54 2.23 3.02 3.11 3.8 2.03 2.73
Serotransferrin iTRAQ 0.36 0.36 0.43 0.57 0.32 0.43 0.48 0.41 0.90 0.006
Quant 0 0 0.05 0.56 0 0.2 0.13 0.14
Haptoglobin iTRAQ 0.39 0.27 0.33 0.43 0.37 0.32 0.47 0.36 0.89 0.02
Quant 0.22 0.14 0.29 0.48 0.62 0.27 0.59 0.33
doi:10.1371/journal.pone.0034107.t004
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(3.1 mg/mg of protein, 95% CI [2.0–4.2]). A similar result was
obtained with apoC-III, which was found to be significantly higher
in the HD patients (22.5 mg/mg of protein, 95% CI [17.4–27.6])
when compared with the healthy controls (7.5 mg/mg of protein,
95% CI [6.1–8.9]). Therefore, the apoC-II/apoC-III ratio was
also found to be significantly higher in the HD patients (ratio of
0.42) when compared with the healthy controls (ratio of 0.25). The
serotransferrin levels in the HDL fraction were significantly lower
in the HD patients (6.7 mg/mg of protein, 95% CI [4.5–8.9]) when
compared with the healthy controls (16.4 mg/mg of protein, 95%
CI [13.1–19.7]). In contrast, there were no confirmed differences
in the haptoglobin levels between the healthy controls (9.5 mg/mg
of protein, 95% CI [5.2–13.8]) and the HD patients (9.8 mg/mg of
protein, 95% CI [5.4–14.2]). Neither age nor the lipid-lowering
drugs taken by some patients were shown to have a significant
impact on our validation data (Table 5).
Discussion
In this study, we investigated the HDL proteome in HD patients
who are considered to have a high risk for CV diseases.
Multidimensional nano-LC/MS/MS was used for the analysis of
the HDL samples, which were labeled with isobaric mass tags
(iTRAQ) to identify the proteins that were differentially expressed
between the HDL fractions of the HD patients and the healthy
volunteers. Earlier studies have identified approximately 50
distinct proteins associated with the HDL fraction, using 2D
electrophoresis and mass spectrometry approaches [19,25–29].
Notably, in our 2D nano-LC/MS/MS approach, we greatly
improved the HDL fraction proteome coverage by identifying 122
proteins associated with the HDL fraction, including 80–90% of
the previously identified proteins [19,25–30]. The proteins
associated with HDL have been implicated in a wide range of
functions, such as lipid metabolism, inflammatory response, the
complement and coagulation cascade, and the activity of the
endopeptidase inhibitor. Among the proteins involved in lipopro-
tein metabolism, we detected several apolipoproteins and enzymes
that are already known to be associated with HDL, such as apoA-
I, apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, apoC-IV, apoD,
apoE, apoJ, apoL-I, apoM, lecithin cholesterol acyl transferase,
and the cholesterol ester transfer protein. In addition, we identified
other proteins associated with the HDL fraction that are related to
the inflammation and oxidative pathways, such as the serum
amyloid proteins, paraoxonase-1 and 3, a1-antitrypsin, and
several complement component proteins.
We identified 40 differentially expressed proteins, with a high
confidence score, between the HD patients and the healthy
volunteer samples; of these proteins, four proteins that were
differentially expressed in all seven HD patients and that were
previously shown to be associated with HDL [28,31] were used to
validate the proteomic analysis. The validation step confirmed the
increase of apoC-II and apoC-III in the HDL fraction of HD
patients compared with the healthy controls. Both apoC-II and
apoC-III were elevated in the HDL fraction of the HD patients,
leading to an increase in the apoC-II/apoC-III ratio. This
observation is surprising when considering the respective functions
Figure 1. The expression analysis of apoC-II, apoC-III, serotransferrin and haptoglobin in the HDL fractions of the healthy
volunteers and the HD patients. The concentration of the proteins in the 14 samples of the discovery set (A) and in the 46 samples of the
validation set (B) were determined using biochemical analyses. The mean is indicated by the horizontal line.
doi:10.1371/journal.pone.0034107.g001
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lipoprotein lipase activity, respectively [32]. VLDL accumulation
related to impaired lipoprotein lipase activity and a decrease in the
plasma apoC-II/apoC-III ratio are classically observed in HD
patients [12]. Nevertheless, the increase of both apoC-II and
apoC-III in the HDL fraction of the HD patients does not predict
the activity of lipoprotein lipase for VLDL delipidation, because
the active form of apoC-II or apoC-III are carried by VLDL [33].
It can be hypothesized that the increase of apoC-II and apoC-III
in the HDL fraction is due to an abnormal transfer of apoC to the
VLDL and the chylomicrons. This accumulation of apoC-II and
apoC-III in the HDL fraction could be a marker of impaired
maturation of the HDL particles, leading not only to dysfunctional
HDL and a potential impairment of reverse cholesterol transport
but also to an overall alteration of lipoprotein metabolism through
modification in the exchange of apoC. Recent studies have
demonstrated that an increase in the plasma apoC-III levels was
positively associated with the smaller sizes of the HDL particles,
and this association was even higher when the elevation of apoC-
III and apoC-II occurred simultaneously [34]. Another study,
performed on HD patients, demonstrated a relationship between a
change in the HDL proteome, including an increase of apoC-III,
and a change in the in vitro HDL functionality, as assessed by their
ability to promote cholesterol efflux in lipid-laden macrophages
[19]. Oxidative stress and inflammation, which are frequently
observed in HD patients, could contribute to the formation of
dysfunctional HDL, as suggested by in vitro studies [35,36]. Finally,
concordant to our study, dysfunctional HDL and the impairment
of reverse cholesterol transport have been shown to be key features
of dyslipidemia in HD and have been shown to contribute to the
high risk for CV diseases [12,19–22].
The atheroprotective effects of HDL are mediated, aside from
the reverse cholesterol transport function, by the antioxidative and
anti-inflammatory properties of HDL [2,4,5]. For example, HDL
may prevent LDL oxidation, a key event in the initiation and
progression of vascular atherosclerotic lesions [3]. Interestingly,
impairment of the HDL antioxidant properties in HD patients was
previously demonstrated using an in vitro LDL oxidation model
[21,22]. Among the processes involved in LDL oxidation, metal
cations, such as iron or copper, may promote the initial step of
lipid peroxidation [37]. Our study identified a cluster of proteins
involved in metal cation homeostasis, such as haptoglobin and
serotransferrin, for which the expression was decreased in the
HDL fraction of the HD patients compared with the healthy
volunteers. In agreement with the previous data shown in plasma
[38], the haptoglobin levels in the HDL fraction of the HD
patients appear downregulated when compared with the controls
in our discovery study population. Haptoglobin, an acute phase
protein, avidly binds to hemoglobin that is released into the
plasma during physiological and pathological hemolysis and
prevents the iron- and heme-mediated oxidative side effects
[39,40]. Unfortunately, the validation step in our independent
Table 5. The differential expression levels of apoC-II, apoC-III, serotransferrin and haptoglobin in the independent healthy and HD
validation study population.
Healthy HD p-value
*
N Concentration N Concentration
(mg/mg of protein) (mg/mg of protein)
Apolipoprotein C-II 23 3.1, 95% CI [2.0–4.2] 23 11.4, 95% CI [8.1–14.8] ,0.0001
Age#56
a 8 3.0, 95% CI [1.2–4.8] 6 8.2, 95% CI [3.1–13.3] ,0.05
Age.56
a 15 3.2, 95% CI [1.6–4.7] 17 12.6, 95% CI [8.2–17.0] ,0.05
No Treatment
b - 3.1, 95% CI [2.0–4.2] 11 9.8, 95% CI [4.6–15.1] ,0.05
With Treatment
b - 3.1, 95% CI [2.0–4.2] 12 13.2, 95% CI [8.3–18.1] ,0.0001
Apolipoprotein C-III 23 7.5, 95% CI [6.1–8.9] 23 22.5, 95% CI [17.4–27.6] ,0.0001
Age#56
a 8 6.3, 95% CI [3.4–9.3] 6 20.5, 95% CI [11.8–29.1] ,0.05
Age.56
a 15 8.1, 95% CI [6.5–9.8] 17 23.2, 95% CI [16.6–29.9] ,0.05
No Treatment
b - 7.5, 95% CI [6.1–8.9] 11 20.7, 95% CI [13.3–28.0] ,0.001
With Treatment
b - 7.5, 95% CI [6.1–8.9] 12 24.5, 95% CI [16.3–32.7] ,0.0001
Serotransferrin 23 16.4, 95% CI [13.1–19.7] 23 6.7, 95% CI [4.5–8.9] ,0.0001
Age#56
a 8 17.8, 95% CI [12.8–22.7] 6 8.0, 95% CI [3.1–13.0] ,0.05
Age.56
a 15 15.6, 95% CI [10.9–20.3] 17 6.2, 95% CI [3.5–8.9] ,0.001
No Treatment
b - 16.4, 95% CI [13.1–19.7] 11 6.9, 95% CI [4.1–9.9] ,0.001
With Treatment
b - 16.4, 95% CI [13.1–19.7] 12 6.4, 95% CI [2.4–10.3] ,0.001
Haptoglobin 23 9.5, 95% CI [5.2–13.8] 23 9.8, 95% CI [5.4–14.2] NS
Age#56
a 8 10.3, 95% CI [1.9–18.6] 6 9.0, 95% CI [1.5–16.4] NS
Age.56
a 15 9.0, 95% CI [3.2–14.7] 17 10.0, 95% CI [4.2–16.0] NS
No Treatment
b - 9.5, 95% CI [5.2–13.8] 11 6.6, 95% CI [2.2–10.9] NS
With Treatment
b - 9.5, 95% CI [5.2–13.8] 12 13.0, 95% CI [5.0–21.1] NS
*Mann-Whitney test.
aHealthy and HD patient groups were divided into patients under the age of 56 and patients above the age of 56.
bHD patient group was divided into patients treated with lipid-lowering drugs and patients without treatment, and each HD subgroup was compared with the healthy
patient group.
doi:10.1371/journal.pone.0034107.t005
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between the groups. However, the haptoglobin levels should be
interpreted with caution in the HD patients, since many conditions
such as hemolysis, folate deficiency, liver disease, anemia, infection
or inflammation can lead to haptoglobin variations. These
confounding factors could explain the dissociation observed for
the haptoglobin levels between the discovery and the validation
study populations. Serotransferrin, the major iron binding protein,
transports iron between the sites of absorption, storage, and
utilization and delivers the iron required for cellular processes
[41]. Interestingly, serotransferrin has already been shown to be
associated with HDL, using both western blot and proteomic
analyses [28,42]. Notably, the in vitro oxidation of LDL by copper
was inhibited by HDL containing serotransferrin and ceruloplas-
min. In contrast, the removal of the lipoproteins containing
serotransferrin or ceruloplasmin reduced the ability of the
lipoproteins to inhibit the oxidation of LDL [42]. Therefore, it
could be hypothesized that the decrease of serotransferrin in the
HDL fraction of the HD patients leads to decreased protection
against LDL oxidation.
In conclusion, we showed that HD patients exhibit major
modifications of their HDL proteome, in addition to the
quantitative decrease of HDL cholesterol. When comparing a
fixed amount of HDL-associated proteins, 40 proteins, primarily
involved in lipid metabolism, the inflammation pathway, comple-
ment activation, and metal cation homeostasis, appear to be
differentially expressed between the HD patients and the healthy
volunteers. The expression level of apoC-II, apoC-III, and
serotransferrin was validated in an independent population set,
improving the reliability of our findings. Note that chronic HD is a
complex therapy, and the comparison of the HDL proteome
between patients undergoing HD and healthy subjects does not
allow us to distinguish the effects of ESRD and HD itself.
Although further investigations with a larger number of subjects
will be needed to determine whether the proteins identified in this
study can be used as relevant CV-risk biomarkers, we identified
proteins with a potential relevance to the pathways linked to HDL
dysfunction in chronic HD patients.
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